1
|
Potasso L, Perakakis N, Lamprinou A, Polyzou E, Kassanos D, Peter A, Päth G, Seufert J, Laubner K. Clinical Impact of the TCF7L2 Gene rs7903146 Type 2 Diabetes
Mellitus Risk Polymorphism in Women with Gestational Diabetes Mellitus: Impaired
Glycemic Control and Increased Need of Insulin Therapy. Exp Clin Endocrinol Diabetes 2019; 128:663-666. [DOI: 10.1055/a-1008-9223] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Abstract
Background The single nucleotide polymorphism in TCF7L2 rs7903146 is
associated with an increased risk of type 2 diabetes mellitus and gestational
diabetes mellitus. Mechanisms by which this mutation acts, and its impact on the
clinical course of the diseases remain unclear. Here we investigated the
clinical impact of the T risk allele in women with gestational diabetes
mellitus.
Methods We genotyped the C/T polymorphism in 164 Caucasian women
with GDM (German n=114; Greek n=50). The impact of the T allele
on the results of the 75g oral-glucose-tolerance-test, and on the required
therapy (diet/lifestyle or insulin) was investigated.
Results During oral-glucose-tolerance-test, women harboring the T allele
displayed significantly higher glucose values at 60 min (p=0.034) and
were more likely to require insulin therapy even after adjusting for
confounders, such as BMI and age.
Conclusion These results provide evidence that the T risk allele in
TCF7L2 rs7903146 is associated with failure in early postprandial glycemic
control and requirement of insulin therapy in women with gestational diabetes
mellitus, even after adjusting for confounding factors such BMI and age.
Collapse
Affiliation(s)
- Laura Potasso
- Division of Endocrinology and Diabetology, Department of Medicine II,
Medical Center – University of Freiburg, Faculty of Medicine, University
of Freiburg, Freiburg, Germany
| | - Nikolaos Perakakis
- Division of Endocrinology and Diabetology, Department of Medicine II,
Medical Center – University of Freiburg, Faculty of Medicine, University
of Freiburg, Freiburg, Germany
- Current address: Division of Endocrinology, Diabetes and Metabolism,
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston,
Massachusetts
| | - Apostolia Lamprinou
- Department of Internal Medicine, Division of Endocrinology,
Diabetology, Angiology, Nephrology and Clinical Chemistry, University Hospital
Tübingen, Tübingen, Freiburg, Germany
- Institute for Diabetes Research and Metabolic Diseases of the Helmholtz
Centre Munich at the University of Tübingen, Tübingen,
Germany
- German Center for Diabetes Research (DZD), Neuherberg, Freiburg,
Germany
| | - Elektra Polyzou
- University Hospital Attikon, 3rd Department of Obstetrics and
Gynecology, Greece
| | - Dimitrios Kassanos
- University Hospital Attikon, 3rd Department of Obstetrics and
Gynecology, Greece
| | - Andreas Peter
- Department of Internal Medicine, Division of Endocrinology,
Diabetology, Angiology, Nephrology and Clinical Chemistry, University Hospital
Tübingen, Tübingen, Freiburg, Germany
- Institute for Diabetes Research and Metabolic Diseases of the Helmholtz
Centre Munich at the University of Tübingen, Tübingen,
Germany
- German Center for Diabetes Research (DZD), Neuherberg, Freiburg,
Germany
| | - Günter Päth
- Division of Endocrinology and Diabetology, Department of Medicine II,
Medical Center – University of Freiburg, Faculty of Medicine, University
of Freiburg, Freiburg, Germany
| | - Jochen Seufert
- Division of Endocrinology and Diabetology, Department of Medicine II,
Medical Center – University of Freiburg, Faculty of Medicine, University
of Freiburg, Freiburg, Germany
| | - Katharina Laubner
- Division of Endocrinology and Diabetology, Department of Medicine II,
Medical Center – University of Freiburg, Faculty of Medicine, University
of Freiburg, Freiburg, Germany
| |
Collapse
|